02:28 ETWorld-First EXO 001 Exosome Platform Enables In Vivo Multi-Target CAR-T for Solid Tumorsprnewswire·Feb 13 at 01:28 AM688520+2.11%上海细胞治疗集团股份有限公司
Sinocelltech released its semi-annual performance report, with a net loss attributable to the parent company of 33.77 million yuan, turning from profit to loss year-on-yearZhitong·Aug 28, 2025 at 05:24 AM688520+2.11%
Guotai Junan Securities: China's innovative drugs are in the early stage of realizing innovative achievements, optimistic about the potential emergence of the next blockbuster product in specific segmentsZhitong·Aug 13, 2025 at 10:38 PM01177-0.59%01530-3.69%
Sinocelltech: SCT640C injection has received approval for clinical trialsZhitong·Jul 29, 2025 at 03:13 AM688520+2.11%
Sinocelltech's subsidiary product SCT640C has received approval for clinical drug trialsZhitong·Jul 24, 2025 at 03:05 AM688520+2.11%
The three major indices of A-shares in Shanghai and Shenzhen fluctuated upwards in the first half of the day, with bank stocks steadily risingAASTOCKS·Jul 3, 2025 at 10:30 PM601398-1.96%01398-1.70%
Innovative drug concept stocks are repeatedly active, Thalys has three consecutive limit-upsZhitong·Jul 2, 2025 at 08:42 PM300485+3.29%603716+3.38%
Sinocelltech's subsidiary product SCTB39G has received the drug clinical trial approval noticeZhitong·Jun 25, 2025 at 04:52 AM688520+2.11%
Sinocelltech's subsidiary product SCTB39-1 has received approval for clinical drug trialsZhitong·Jun 17, 2025 at 04:14 AM688520+2.11%
Overview of CAR-T therapy concept stocks with the highest increase in trading volumeZhitong·Jun 7, 2025 at 11:56 PM000566-1.51%688520+2.11%
The concept of innovative drugs warmed up in the afternoon, with CSBIO rising over 15%, reaching a historic highZhitong·Jun 6, 2025 at 12:27 AM688520+2.11%300255+3.53%
Sinocelltech plans to raise no more than 900 million yuan through a private placement to its controlling shareholderZhitong·Jun 5, 2025 at 07:43 AM688520+2.11%
Sinocelltech: Shareholders plan to reduce their holdings by 0.50% of the company's sharesZhitong·Apr 22, 2025 at 07:30 AM688520+2.11%
Sinocelltech: Lan Zhanghua resigns from the position of Deputy General Manager of the companyZhitong·Mar 31, 2025 at 03:07 AM688520+2.11%
Sinocelltech's subsidiary product SCTT11 has received the drug clinical trial approval noticeZhitong·Mar 6, 2025 at 04:23 AM688520+2.11%
